StocksMedium•16 November 2026•
1 min read
Unicycive Therapeutics Beats Q3 Earnings Estimates
Key Facts
1Unicycive Therapeutics reported a GAAP EPS loss of $0.25, beating analyst estimates by $0.10.
Unicycive Therapeutics reported a GAAP EPS loss of $0.25 for its third-quarter financial results, beating analyst estimates by $0.10. Seeking Alpha reported that the results for the fiscal period ending September 2026 showed better cost management or lower expenses than anticipated by the market.
UNCY closed at $3.55 on November 13, 2026, having reached a day high of $3.69 and a low of $3.52. As of September 30, 2026, the company's cash, cash equivalents, and marketable securities totaled $59 million, providing a projected operational runway beyond 2027.